Loading...
XNAS
GRFS
Market cap4.30bUSD
Apr 10, Last price  
6.52USD
1D
-5.92%
1Q
-10.56%
Jan 2017
-59.43%
IPO
1.88%
Name

Grifols SA

Chart & Performance

D1W1MN
P/E
64.50
P/S
0.58
EPS
0.09
Div Yield, %
—
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
8.00%
Revenues
6.59b
+8.71%
524,277,000648,797,000703,291,000814,311,000913,186,000990,730,0001,795,613,0002,620,944,0002,741,732,0003,355,384,0003,934,563,0004,049,830,0004,318,073,0004,486,724,0005,098,691,0005,340,038,0004,933,118,0006,063,967,0006,591,977,000
Net income
59m
-71.52%
25,556,00045,394,00087,774,000121,728,000147,972,000115,513,00050,307,000256,686,000345,551,000470,253,000532,145,000545,456,000662,700,000596,642,000625,146,000708,990,000265,327,000208,279,00059,315,000
CFO
208m
P
119,724,00049,076,00088,644,00073,409,00088,180,000104,252,000220,228,000507,118,000592,011,000978,928,000742,778,000553,278,000841,746,000737,428,000568,933,0001,110,336,000596,975,000-10,867,000208,283,000
Dividend
Jun 03, 20210.4385 USD/sh
Earnings
May 12, 2025

Profile

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
URL
https://www.grifols.com/
IPO date
May 17, 2006
Employees
23,631
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,591,977
8.71%
6,063,967
22.92%
Cost of revenue
5,752,222
4,193,577
Unusual Expense (Income)
NOPBT
839,755
1,870,390
NOPBT Margin
12.74%
30.84%
Operating Taxes
43,349
90,111
Tax Rate
5.16%
4.82%
NOPAT
796,406
1,780,279
Net income
59,315
-71.52%
208,279
-21.50%
Dividends
(592)
Dividend yield
Proceeds from repurchase of equity
(3,459)
BB yield
Debt
Debt current
1,013,481
681,273
Long-term debt
10,330,852
10,085,796
Deferred revenue
13,807
15,123
Other long-term liabilities
1,919,634
1,001,788
Net debt
10,133,508
7,626,942
Cash flow
Cash from operating activities
208,283
(10,867)
CAPEX
(209,538)
(375,560)
Cash from investing activities
(397,636)
(1,978,823)
Cash from financing activities
186,045
(173,493)
FCF
(864,520)
(69,694)
Balance
Cash
645,720
591,235
Long term investments
565,105
2,548,892
Excess cash
881,226
2,836,929
Stockholders' equity
7,214,505
8,619,764
Invested Capital
19,271,512
16,352,845
ROIC
4.47%
12.26%
ROCE
4.17%
9.25%
EV
Common stock shares outstanding
679,092
1,359,610
Price
Market cap
EV
EBITDA
1,281,673
2,278,254
EV/EBITDA
Interest
516,060
362,629
Interest/NOPBT
61.45%
19.39%